CSS
SCMP

Cubist Systematic Strategies’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Cubist Systematic Strategies’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-12,823
Closed -$230K – 2232
2017
Q4 		$230K Buy
12,823
+7,744
+152% +$95.3K 0.01% 1435
2017
Q3 		$60K Buy
+5,079
New +$57K ﹤0.01% 1713
2017
Q1 		– Sell
-8,515
Closed -$115K – 2009
2016
Q4 		$115K Buy
8,515
+5,767
+210% +$80.5K 0.01% 1442
2016
Q3 		$34K Buy
+2,748
New +$32.4K ﹤0.01% 1598
2015
Q4 		– Sell
-12,849
Closed -$255K – 2089
2015
Q3 		$255K Buy
12,849
+1,645
+15% +$37.7K 0.01% 1336
2015
Q2 		$184K Buy
11,204
+1,043
+10% +$18.1K 0.01% 1470
2015
Q1 		$158K Sell
10,161
-14,541
-59% -$225K 0.01% 1595
2014
Q4 		$353K Buy
+24,702
New +$261K 0.02% 1100

Other funds holding SCMP

GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
AIM
Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return

Cubist Systematic Strategies's SCMP Position: Q1 2018 in Review

Cubist Systematic Strategies sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2018, closing a stake of 12,823 shares — an estimated $230K sold.

Cubist Systematic Strategies first reported a position in SCMP in Q4 2014 and held it in 8 quarters. The position peaked at $353K in Q4 2014. 3 funds tracked by Wall St. Rank hold SCMP as of Q1 2018.

  • Cubist Systematic Strategies reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Cubist Systematic Strategies sold 12,823 Sucampo Pharmaceuticals, Inc. shares in Q1 2018, an estimated $230K.
  • Cubist Systematic Strategies first reported a position in Sucampo Pharmaceuticals, Inc. in Q4 2014 and held it in 8 quarters.
  • Cubist Systematic Strategies's Sucampo Pharmaceuticals, Inc. position peaked at $353K in Q4 2014.
  • 3 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2018.

Based on Cubist Systematic Strategies's 13F filing for Q1 2018, filed 15 May 2018.